|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 3.5M 3.01M 2.77M 2.61M 4.89M 331M 4.94M 32.79M 12.77M 162M 13.12M 12.84M 561M | P/E 2026 * |
-0.12x | P/E 2027 * | -0.12x |
|---|---|---|---|---|---|
| Enterprise Value | 3.5M 3.01M 2.77M 2.61M 4.89M 331M 4.94M 32.79M 12.77M 162M 13.12M 12.84M 561M | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
53.62% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
David Cory
CEO | Chief Executive Officer | 62 | 21/07/2025 |
Kun Qian
DFI | Director of Finance/CFO | 44 | 16/05/2025 |
Chun Hua Wang
COO | Chief Operating Officer | 54 | 01/01/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
David Cory
BRD | Director/Board Member | 62 | 21/07/2025 |
Zuie Chin Huang
CHM | Chairman | 61 | 17/11/2025 |
Yue Wu
BRD | Director/Board Member | 62 | 01/04/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.30% | -1.62% | +41.30% | +147.37% | 1,001B | |
| -0.76% | -2.16% | +53.13% | +42.17% | 566B | |
| -0.16% | -1.14% | +19.89% | +61.36% | 393B | |
| +3.82% | +2.29% | +24.04% | +16.53% | 326B | |
| +1.04% | +1.55% | +26.48% | +33.05% | 276B | |
| +1.28% | -0.37% | +25.81% | +15.18% | 277B | |
| +1.87% | +0.87% | -41.49% | -47.26% | 193B | |
| -0.01% | +2.91% | +19.82% | +52.04% | 188B | |
| -0.01% | +4.94% | +18.04% | +64.05% | 158B | |
| Average | +0.18% | +0.35% | +20.78% | +42.72% | 375.2B | |
| Weighted average by Cap. | -0.10% | -0.41% | +29.64% | +66.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -24.73M -21.31M -19.62M -18.42M -34.59M -2.34B -34.96M -232M -90.33M -1.14B -92.79M -90.82M -3.97B | -26.51M -22.85M -21.04M -19.75M -37.09M -2.51B -37.48M -249M -96.85M -1.23B -99.49M -97.38M -4.25B |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
